Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xueshan Qingfei Mixture for Chronic Lung Disease
ChiCTR2100045848Phase 3Recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Apr 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of Xushan Qingfei Mixture in chronic obstructive pulmonary disease (COPD), asthma, chronic cough and 1 more (3 arms), sponsored by The Second Xiangya Hospital. Primary endpoints: Pulmonary function, Inflammatory markers and 1 more. Started Apr 2021; status: recruiting.
02
Drugs
Xushan Qingfei Mixture
03
Conditions
chronic obstructive pulmonary disease (COPD)asthmachronic coughchronic lung disease
Beyond the preview
Go deeper on ChiCTR2100045848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045848.